Please login to the form below

Not currently logged in
Email:
Password:

R&D costs push up ALK Abello's Q2 FY07 pre-tax losses

Danish pharmaceutical company ALK Abello has posted a Q2 FY07 pre-tax loss of DKK 29m (USD 5.3m), an increase on a Q2 FY06 loss of DMK 24m, due to increased costs for R&D and sales and marketing.

Danish pharmaceutical company ALK Abello has posted a Q2 FY07 pre-tax loss of DKK 29m (USD 5.3m), an increase on a Q2 FY06 loss of DMK 24m, due to increased costs for R&D and sales and marketing.

SME Direkt analysts had expected a pre-tax loss of DKK 15m (USD 2.7m).

Sales increased 11 per cent to reach DKK 373m (USD 67.5m), down slightly on market expectations of DMK 377m (USD 68.3m).

The group posted an operating loss of DKK 35m (USD 6.3m), compared with DKK 31m in Q2 FY06 and was below expectations for a DMK 24m (USD 4.4m) loss.

ALK Abello reiterated its previous FY07 sales guidance of approximately DKK 1.7bn (USD 307.8m) and a pre-tax profit of DKK 230 to DKK 250m (USD 41.7m to USD 45.3m).

The company said the launch of its tablet-based grass pollen allergy vaccine Grazax was progressing according to plan. Sales of the drug amounted to DKK 19m (USD 3.4m) in H1 FY07.

ALK Abello said its year-on-year increase in costs for sales, marketing and administration was related to Grazax, while continuing development of the vaccine also augmented R&D costs.

Sales growth in the period was helped by an active allergy season, according to the firm.

22nd August 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

Beyond the event
...
Anthill Agency and Actando partnership to Transform Pharma's Digital Skills
Anthill Agency, a leading life sciences digital agency, today announced the launch of the Anthill Academy™ and partnership with Actando's PharmAcademy....
Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...

Infographics